JP2023096044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023096044A5 JP2023096044A5 JP2023081001A JP2023081001A JP2023096044A5 JP 2023096044 A5 JP2023096044 A5 JP 2023096044A5 JP 2023081001 A JP2023081001 A JP 2023081001A JP 2023081001 A JP2023081001 A JP 2023081001A JP 2023096044 A5 JP2023096044 A5 JP 2023096044A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- seq
- fusion protein
- amino acid
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564145P | 2017-09-27 | 2017-09-27 | |
| US62/564,145 | 2017-09-27 | ||
| JP2020517588A JP2020536518A (ja) | 2017-09-27 | 2018-09-27 | 免疫調節融合タンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517588A Division JP2020536518A (ja) | 2017-09-27 | 2018-09-27 | 免疫調節融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023096044A JP2023096044A (ja) | 2023-07-06 |
| JP2023096044A5 true JP2023096044A5 (https=) | 2024-02-19 |
| JP7702445B2 JP7702445B2 (ja) | 2025-07-03 |
Family
ID=65902489
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517588A Withdrawn JP2020536518A (ja) | 2017-09-27 | 2018-09-27 | 免疫調節融合タンパク質 |
| JP2023081001A Active JP7702445B2 (ja) | 2017-09-27 | 2023-05-16 | 免疫調節融合タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517588A Withdrawn JP2020536518A (ja) | 2017-09-27 | 2018-09-27 | 免疫調節融合タンパク質 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11834492B2 (https=) |
| EP (1) | EP3688037A4 (https=) |
| JP (2) | JP2020536518A (https=) |
| KR (1) | KR102757384B1 (https=) |
| CN (2) | CN118652350A (https=) |
| AU (2) | AU2018338612A1 (https=) |
| BR (1) | BR112020006115A2 (https=) |
| CA (1) | CA3077223A1 (https=) |
| EA (1) | EA202090838A1 (https=) |
| IL (1) | IL273626B2 (https=) |
| MX (1) | MX2020003672A (https=) |
| SG (1) | SG11202002826VA (https=) |
| WO (1) | WO2019067770A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118307682A (zh) | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| CN114945586B (zh) * | 2020-01-21 | 2025-01-28 | 宁波新致生物科技有限公司 | 一种药物组合物及其用途 |
| CN113480662B (zh) * | 2021-06-29 | 2022-07-22 | 北京双因生物科技有限公司 | 包含cd40抗体和il-15的融合蛋白及其制备方法和用途 |
| CN116143946B (zh) * | 2022-01-05 | 2025-12-09 | 赛德特生物制药有限公司 | 一种用于免疫治疗的新型融合蛋白、基因、重组载体、宿主细胞及应用 |
| WO2025148750A1 (zh) * | 2024-01-08 | 2025-07-17 | 上药生物治疗（香港）有限公司 | 膜表达il-10及其用途 |
| WO2025221843A1 (en) * | 2024-04-17 | 2025-10-23 | Baylor College Of Medicine | Methods and compositions for suppressing immune cell activation |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| AU3830895A (en) | 1994-10-07 | 1996-05-02 | Amgen Boulder Inc. | Dimeric il-4 inhibitors |
| AUPN477695A0 (en) | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| GB9626029D0 (en) | 1996-12-14 | 1997-01-29 | Univ Leeds | EVH-1 vectors |
| US5998598A (en) | 1997-03-10 | 1999-12-07 | The United States Of America, As Represented By The Department Of Health And Human Services | Immunoadhesins and methods of production and use thereof |
| JP2001515360A (ja) | 1997-04-18 | 2001-09-18 | バイオジェン，インコーポレイテッド | ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 |
| CA2330939A1 (en) | 1998-06-16 | 1999-12-23 | Biogen, Inc. | Variant type ii tgf-beta receptor fusion proteins and methods |
| US7083950B2 (en) | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| ATE407697T1 (de) | 1999-07-13 | 2008-09-15 | Bolder Biotechnology Inc | Erythropoietin immunglobulin fusionsproteine |
| JP4793971B2 (ja) | 1999-08-09 | 2011-10-12 | メルク パテント ゲーエムベーハー | 複合サイトカイン−抗体複合体 |
| US7638604B2 (en) | 2001-02-23 | 2009-12-29 | Genetics Institute, Llc | Monoclonal antibodies against interleukin-22 |
| US20030125251A1 (en) | 2001-06-21 | 2003-07-03 | Wakefield Lalage M. | Transforming growth factor beta (TGF-beta) antagonist selectively neutralizes "pathological" TGF-beta |
| WO2003066002A2 (en) * | 2002-02-08 | 2003-08-14 | University Of Medicine And Dentistry Of New Jersey | IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION |
| WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
| US20090111146A1 (en) * | 2003-09-02 | 2009-04-30 | National Institute Of Advanced Industrial Science | Antibody Drug |
| US20090155267A1 (en) * | 2005-02-09 | 2009-06-18 | Apollo Life Sciences Limited | Molecule and chimeric molecules thereof |
| EP1858923A4 (en) * | 2005-02-14 | 2008-10-15 | Apollo Life Sciences Ltd | MOLECULAR AND CHIMERAL MOLECULES FROM IT |
| CN101146825A (zh) * | 2005-02-14 | 2008-03-19 | 阿波罗生命科学有限公司 | 分子及其嵌合分子 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US20090175819A1 (en) * | 2005-11-15 | 2009-07-09 | Apollo Life Sciences Limited | Molecule and chimeric molecules thereof |
| CN105131127B (zh) | 2007-05-30 | 2018-09-07 | 浦项工科大学校产学协力团 | 免疫球蛋白融合蛋白 |
| EP2171062A1 (en) | 2007-06-15 | 2010-04-07 | Genzyme Corporation | Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor |
| EP2293667A4 (en) * | 2008-05-27 | 2012-07-18 | Kyowa Hakko Kirin Co Ltd | INTERLEUKIN 10-RECEPTOR (IL-10R) ANTIBODY AND USE PROCESS |
| NZ590667A (en) | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| EP2326670A4 (en) | 2008-09-17 | 2014-04-16 | Nat Res Council Canada | HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY |
| KR102020018B1 (ko) | 2009-03-02 | 2019-09-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 종양 선택적 ｅ１ａ 및 ｅ１ｂ 돌연변이 |
| CA3083324A1 (en) | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CN110563850A (zh) | 2012-04-30 | 2019-12-13 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
| CA3081073C (en) | 2013-03-12 | 2023-09-12 | Biocon Ltd. | Fusion immunomodulatory proteins and methods for making same |
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| WO2015077540A2 (en) | 2013-11-21 | 2015-05-28 | The Brigham And Women's Hospital, Inc. | Compositions and methods for treating pulmonary hypertension |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| AU2015364396B2 (en) | 2014-12-19 | 2018-08-09 | Alkermes, Inc. | Single chain Fc fusion proteins |
| CA2979973A1 (en) * | 2015-04-29 | 2016-11-03 | Mediolanum Farmaceutici S.P.A. | A soluble chimeric interleukin-10 receptor and therapeutic use thereof |
| US20200231652A1 (en) | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| CN118307682A (zh) | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| US10232053B2 (en) * | 2016-12-30 | 2019-03-19 | Trieza Therapeutics, Inc. | Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer |
-
2018
- 2018-09-27 JP JP2020517588A patent/JP2020536518A/ja not_active Withdrawn
- 2018-09-27 SG SG11202002826VA patent/SG11202002826VA/en unknown
- 2018-09-27 MX MX2020003672A patent/MX2020003672A/es unknown
- 2018-09-27 EP EP18862997.6A patent/EP3688037A4/en not_active Withdrawn
- 2018-09-27 US US16/651,079 patent/US11834492B2/en active Active
- 2018-09-27 CN CN202410618028.5A patent/CN118652350A/zh active Pending
- 2018-09-27 WO PCT/US2018/053197 patent/WO2019067770A1/en not_active Ceased
- 2018-09-27 EA EA202090838A patent/EA202090838A1/ru unknown
- 2018-09-27 CN CN201880075263.5A patent/CN111511769B/zh active Active
- 2018-09-27 AU AU2018338612A patent/AU2018338612A1/en not_active Abandoned
- 2018-09-27 BR BR112020006115-8A patent/BR112020006115A2/pt not_active Application Discontinuation
- 2018-09-27 IL IL273626A patent/IL273626B2/en unknown
- 2018-09-27 KR KR1020207011933A patent/KR102757384B1/ko active Active
- 2018-09-27 CA CA3077223A patent/CA3077223A1/en active Pending
-
2023
- 2023-05-16 JP JP2023081001A patent/JP7702445B2/ja active Active
- 2023-10-25 US US18/494,508 patent/US20240052016A1/en active Pending
-
2025
- 2025-10-09 AU AU2025248681A patent/AU2025248681A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023096044A5 (https=) | ||
| ES2704411T3 (es) | Proteínas de fusión inmunomoduladoras y procedimientos de fabricación de las mismas | |
| JP2019531728A5 (https=) | ||
| JP2020536518A5 (https=) | ||
| JP6643394B2 (ja) | Ｍ９７１キメラ抗原受容体 | |
| JP6613304B2 (ja) | 抗ｃｄ２７６抗体（ｂ７ｈ３） | |
| ES2207278T3 (es) | Heterominicuerpos. | |
| IL273626B1 (en) | Fusion proteins and immune modulators | |
| JP2021514677A5 (https=) | ||
| JP2023552851A (ja) | 二重特異性抗体およびその適用 | |
| JP2022542543A (ja) | 抗ｄｌｌ３キメラ抗原受容体及びその使用 | |
| US20190365805A1 (en) | Chimeric antigen receptors and uses thereof | |
| CN112601546B (zh) | Plap-car-效应细胞 | |
| CN110520533A (zh) | 治疗癌症的vegfr-2 car免疫细胞 | |
| JP2009525762A (ja) | 二価性ＥｒｂＢリガンド結合分子ならびにその調製および使用のための方法 | |
| CN114040927A (zh) | 结合cd33的多肽及其用途 | |
| US20240270812A1 (en) | Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies | |
| Sun et al. | From anti-HER-2 to anti-HER-2-CAR-T cells: an evolutionary immunotherapy approach for gastric cancer | |
| KR20160085324A (ko) | Her2를 표적화하는 1가 항원 결합 작제물을 사용하는 방법 | |
| JPWO2022121239A5 (https=) | ||
| CN116284430A (zh) | 靶向肿瘤的il15融合蛋白及其应用 | |
| CN115052897B (zh) | PLAP-CD3ε双特异性抗体 | |
| CN1312177C (zh) | 肿瘤相关蛋白的抗原表位及其编码基因与应用 | |
| CN116948012B (zh) | 增强细胞功能的cd16抗剪切突变体 | |
| JP2022503621A5 (https=) |